# Journal of Clinical Oncology

Source: https://onco.cc/journals/jco/  
OnCo record `jco` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Journal of Clinical Oncology is ASCO's flagship journal and the workhorse of clinical oncology, publishing trials, ASCO guidelines, and the abstract supplements for the ASCO Annual Meeting.

## Summary

JCO publishes three issues a month, carrying phase 2 and 3 trials across all tumour types, ASCO clinical practice guidelines (for example on immune-related adverse events), health-services and survivorship research, and the annual-meeting abstract supplements that make it the most cited oncology journal by volume. Hybrid access; guidelines are free. Sister titles include JCO Precision Oncology, JCO Oncology Practice and JCO Global Oncology.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: JCO; J Clin Oncol; src-jco
- Publisher: American Society of Clinical Oncology
- Scope: clinical oncology
- Access: hybrid

## Notes

- Holds: ASCO flagship journal: trials, guidelines (including living guidelines) and long-term follow-up of cooperative-group studies. Access: Paywalled; guidelines and many trials free.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Journal_of_Clinical_Oncology
- ASCO guidelines: https://www.asco.org/practice-patients/guidelines

## Connected records

- collections: [ASCO clinical practice guidelines](https://onco.cc/collections/asco-guidelines/), [ASCO Meeting Library](https://onco.cc/collections/src-asco-meeting-library/)
- journals: [JCO clinical cancer informatics](https://onco.cc/journals/jco-clinical-cancer-informatics/), [JCO Precision Oncology](https://onco.cc/journals/jco-precision-oncology/)
- institutions: [American Society of Clinical Oncology (ASCO)](https://onco.cc/institutions/asco/)
- key papers: [AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children](https://onco.cc/key-papers/paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009/), [AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults](https://onco.cc/key-papers/paper-aall0232-larsen-jco-2016/), [AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults](https://onco.cc/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/), [AALL1231: bortezomib in newly diagnosed T-cell acute lymphoblastic leukaemia and lymphoma, with cranial radiotherapy removed](https://onco.cc/key-papers/paper-aall1231-bortezomib-t-all-teachey-jco-2022/), [AALL1331: blinatumomab added to chemotherapy in low-risk first relapse of childhood B-ALL](https://onco.cc/key-papers/paper-aall1331-low-risk-hogan-jco-2023/), [AAML0531: gemtuzumab ozogamicin added to chemotherapy for children and adolescents with acute myeloid leukaemia](https://onco.cc/key-papers/paper-aaml0531-gemtuzumab-gamis-jco-2014/), [AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia](https://onco.cc/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/), [Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI](https://onco.cc/key-papers/paper-kuhl-j-clin-oncol/), [Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma](https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/), [Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial](https://onco.cc/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/), [ACNS0121: conformal radiotherapy for paediatric ependymoma, chemotherapy for incompletely resected tumours and observation after complete resection](https://onco.cc/key-papers/paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019/), [ACNS0331: reduced-dose and reduced-volume radiotherapy with chemotherapy for average-risk medulloblastoma](https://onco.cc/key-papers/paper-acns0331-michalski-jco-2021/), [ACNS0333: high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumour](https://onco.cc/key-papers/paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020/), [ACNS1123: response-based reduced radiotherapy for localised CNS non-germinomatous germ cell tumours](https://onco.cc/key-papers/paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019/), [Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial](https://onco.cc/key-papers/paper-parsons-j-clin-oncol/), [Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT](https://onco.cc/key-papers/paper-soft-text-j-clin-oncol-2023-update/), [Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update](https://onco.cc/key-papers/paper-aphinity-j-clin-oncol-2024-update/), [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations](https://onco.cc/key-papers/paper-aeneas-j-clin-oncol-2022/), [AEWS0031: randomised trial of interval-compressed chemotherapy for localised Ewing sarcoma](https://onco.cc/key-papers/paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012/), [Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia](https://onco.cc/key-papers/paper-hillmen-j-clin-oncol/), [ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/), [Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations](https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/), [American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer](https://onco.cc/key-papers/paper-asco-cap-er-pr-testing-guideline-jco-2010/), [Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://onco.cc/key-papers/paper-park-j-clin-oncol/), [Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study](https://onco.cc/key-papers/paper-nct05379595-j-clin-oncol-2026/), [AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours](https://onco.cc/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/), [ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma](https://onco.cc/key-papers/paper-anbl0531-twist-jco-2019/), [ANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma](https://onco.cc/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/), [ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma](https://onco.cc/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/), [Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma](https://onco.cc/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/), [ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer](https://onco.cc/key-papers/paper-arches-j-clin-oncol-2019/), [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/), [AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma](https://onco.cc/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/), [Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report](https://onco.cc/key-papers/paper-dix-j-clin-oncol/), [AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer](https://onco.cc/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/), [Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia](https://onco.cc/key-papers/paper-azacitidine-aml-j-clin-oncol-2010/), [Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-andre-j-clin-oncol/), [Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/), [BMT CTN 1102: biologic assignment trial of reduced-intensity transplant by donor availability in patients aged 50 to 75 with advanced myelodysplastic syndrome](https://onco.cc/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/), [Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025/), [Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)](https://onco.cc/key-papers/paper-alta-jco-2017/), [Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement](https://onco.cc/key-papers/paper-kim-j-clin-oncol/), [C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed](https://onco.cc/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/), [Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline](https://onco.cc/key-papers/paper-braun-j-clin-oncol/), [Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial](https://onco.cc/key-papers/paper-adams-j-clin-oncol/), [Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial](https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/), [Carboplatin dosage: prospective evaluation of a simple formula based on renal function](https://onco.cc/key-papers/paper-calvert-j-clin-oncol/), [Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma](https://onco.cc/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/), [Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status](https://onco.cc/key-papers/paper-kras-colorectal-j-clin-oncol-2011/), [CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up](https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/), [Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma](https://onco.cc/key-papers/paper-kurtz-j-clin-oncol/), [Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours](https://onco.cc/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/), [Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer](https://onco.cc/key-papers/paper-aggarwal-t-sccpc-jco-2018/), [Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer](https://onco.cc/key-papers/paper-atchley-brca-status-triple-negative-jco-2008/), [CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial](https://onco.cc/key-papers/paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025/), [Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas](https://onco.cc/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/), [COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-herbst-j-clin-oncol/), [COG P9641: surgery alone or with restricted chemotherapy for low-risk neuroblastoma](https://onco.cc/key-papers/paper-p9641-low-risk-neuroblastoma-strother-jco-2012/), [CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia](https://onco.cc/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/), [CSCO and ASCO guideline: chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma](https://onco.cc/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/), [Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry](https://onco.cc/key-papers/paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009/), [Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)](https://onco.cc/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/), [Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H](https://onco.cc/key-papers/paper-salama-j-clin-oncol/), [Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma](https://onco.cc/key-papers/paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023/), [Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study](https://onco.cc/key-papers/paper-tropion-lung05-j-clin-oncol-2025/), [Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma](https://onco.cc/key-papers/paper-shindo-germline-sporadic-pancreatic-jco-2017/), [DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer](https://onco.cc/key-papers/paper-destiny-lung02-goto-jco-2023/), [DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours](https://onco.cc/key-papers/paper-destiny-pantumor02-jco-2024/), [Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study](https://onco.cc/key-papers/paper-philip-j-clin-oncol/), [Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)](https://onco.cc/key-papers/paper-ambrosone-j-clin-oncol/), [Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303](https://onco.cc/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/), [DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer](https://onco.cc/key-papers/paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009/), [DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma](https://onco.cc/key-papers/paper-dreamseq-jco-2023/), [DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer](https://onco.cc/key-papers/paper-duo-e-jco-2023/), [Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001](https://onco.cc/key-papers/paper-nct03157128-j-clin-oncol-2024-update/), [E3A06: lenalidomide versus observation in smouldering multiple myeloma](https://onco.cc/key-papers/paper-e3a06-lenalidomide-smouldering-lonial-jco-2020/), [Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial](https://onco.cc/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/), [Early relapse of follicular lymphoma after R-CHOP defines patients at high risk for death: an analysis from the National LymphoCare Study](https://onco.cc/key-papers/paper-casulo-pod24-follicular-lymphoma-jco-2015/), [Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy](https://onco.cc/key-papers/paper-chua-j-clin-oncol/), [ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer](https://onco.cc/key-papers/paper-e3311-transoral-surgery-ferris-jco-2022/), [Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial](https://onco.cc/key-papers/paper-van-waart-j-clin-oncol/), [Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer](https://onco.cc/key-papers/paper-badwe-j-clin-oncol/), [Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017/), [Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study](https://onco.cc/key-papers/paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023/), [Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial](https://onco.cc/key-papers/paper-nct06198751-j-clin-oncol-2026/), [Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study](https://onco.cc/key-papers/paper-keynote-158-j-clin-oncol-2019/), [Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study](https://onco.cc/key-papers/paper-nct04395677-j-clin-oncol-2024/), [EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes](https://onco.cc/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/), [Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial](https://onco.cc/key-papers/paper-mao-j-clin-oncol-2015/), [EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients](https://onco.cc/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/), [EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor](https://onco.cc/key-papers/paper-emerald-elacestrant-jco-2022/), [Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study](https://onco.cc/key-papers/paper-tabernero-j-clin-oncol/), [Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer](https://onco.cc/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/), [EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up](https://onco.cc/key-papers/paper-eortc-26951-van-den-bent-jco-2013/), [EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T](https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/), [Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer](https://onco.cc/key-papers/paper-pik3ca-colorectal-j-clin-oncol-2013/), [Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial](https://onco.cc/key-papers/paper-wen-j-clin-oncol/), [EXAM: cabozantinib in progressive medullary thyroid cancer](https://onco.cc/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/), [Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-oktay-j-clin-oncol/), [Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy](https://onco.cc/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/), [Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer](https://onco.cc/key-papers/paper-ramsey-j-clin-oncol/), [First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors](https://onco.cc/key-papers/paper-hassan-j-clin-oncol/), [First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation](https://onco.cc/key-papers/paper-nct04561362-j-clin-oncol-2025/), [First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial](https://onco.cc/key-papers/paper-nct04129502-j-clin-oncol-2025/), [Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study](https://onco.cc/key-papers/paper-keynote-042-j-clin-oncol-2023-update/), [Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50](https://onco.cc/key-papers/paper-keynote-024-189-j-clin-oncol-2021-update/), [Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer](https://onco.cc/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/), [Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer](https://onco.cc/key-papers/paper-noronha-j-clin-oncol/), [Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial](https://onco.cc/key-papers/paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002/), [Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer](https://onco.cc/key-papers/paper-castro-germline-brca-prostate-outcomes-jco-2013/), [Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline](https://onco.cc/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/), [Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study](https://onco.cc/key-papers/paper-nct04576455-j-clin-oncol-2024/), [GOG 174: weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia](https://onco.cc/key-papers/paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011/), [GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma](https://onco.cc/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/), [GRAALL-2005: randomised hyperfractionated cyclophosphamide in a paediatric-inspired adult ALL protocol](https://onco.cc/key-papers/paper-graall-2005-huguet-jco-2018/), [GROINSS-V II: radiotherapy versus inguinofemoral lymphadenectomy for vulvar cancer with sentinel node micrometastases](https://onco.cc/key-papers/paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021/), [GROINSS-V: sentinel node dissection is safe in early-stage vulvar cancer](https://onco.cc/key-papers/paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008/), [HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib](https://onco.cc/key-papers/paper-her2climb-brain-lin-jco-2020/), [HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer](https://onco.cc/key-papers/paper-her2climb-05-j-clin-oncol-2026/), [HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy](https://onco.cc/key-papers/paper-nct04619004-j-clin-oncol-2023/), [Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum](https://onco.cc/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/), [Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update](https://onco.cc/key-papers/paper-wolff-j-clin-oncol-2018/), [Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update](https://onco.cc/key-papers/paper-wolff-j-clin-oncol/), [IELSG37: omission of radiotherapy in primary mediastinal B-cell lymphoma after a negative PET scan](https://onco.cc/key-papers/paper-ielsg37-pmbcl-martelli-jco-2024/), [IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia](https://onco.cc/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/), [IGCCCG Update Consortium: predicting outcomes in men with metastatic non-seminomatous germ cell tumours](https://onco.cc/key-papers/paper-igcccg-update-gillessen-jco-2021/), [IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy](https://onco.cc/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/), [Imatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin](https://onco.cc/key-papers/paper-hodi-imatinib-kit-melanoma-jco-2013/), [Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)](https://onco.cc/key-papers/paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010/), [Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405](https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/), [Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)](https://onco.cc/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/), [Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations](https://onco.cc/key-papers/paper-archer-1050-os-jco-2018/), [Individual patient data meta-analysis of microsatellite instability as a biomarker in gastric cancer (MAGIC, CLASSIC, ARTIST, ITACA-S)](https://onco.cc/key-papers/paper-pietrantonio-msi-gastric-meta-analysis-jco-2019/), [Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma](https://onco.cc/key-papers/paper-amit-induction-chemotherapy-response-snuc-jco-2019/), [Inherited breast cancer in Nigerian women](https://onco.cc/key-papers/paper-zheng-nigerian-inherited-breast-cancer-jco-2018/), [Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer](https://onco.cc/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/), [Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring](https://onco.cc/key-papers/paper-seligmann-j-clin-oncol/), [Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-ferrell-j-clin-oncol/), [Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline](https://onco.cc/key-papers/paper-mao-j-clin-oncol/), [Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline](https://onco.cc/key-papers/paper-carlson-j-clin-oncol/), [Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline](https://onco.cc/key-papers/paper-lyman-j-clin-oncol/), [InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer](https://onco.cc/key-papers/paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020/), [Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia](https://onco.cc/key-papers/paper-interfant-06-pieters-jco-2019/), [Intergroup 0099: chemoradiotherapy versus radiotherapy in advanced nasopharyngeal cancer](https://onco.cc/key-papers/paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998/), [International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers](https://onco.cc/key-papers/paper-igcccg-classification-jco-1997/), [Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study](https://onco.cc/key-papers/paper-nct03897881-j-clin-oncol-2026-update/), [INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib](https://onco.cc/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/), [KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer](https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/), [KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma](https://onco.cc/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/), [KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/), [KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-keynote-629-pembrolizumab-cscc-grob-jco-2020/), [Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour](https://onco.cc/key-papers/paper-heinrich-kit-mutation-imatinib-response-jco-2003/), [KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer](https://onco.cc/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/), [Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP](https://onco.cc/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/), [Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma](https://onco.cc/key-papers/paper-ballman-j-clin-oncol/), [Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study](https://onco.cc/key-papers/paper-nct04395677-j-clin-oncol-2026-update/), [Long-term follow-up of a large active surveillance cohort of patients with prostate cancer (Sunnybrook)](https://onco.cc/key-papers/paper-klotz-active-surveillance-jco-2015/), [Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials](https://onco.cc/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/), [Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype](https://onco.cc/key-papers/paper-symmans-rcb-long-term-prognosis-subtype-jco-2017/), [Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial](https://onco.cc/key-papers/paper-opra-j-clin-oncol-2024/), [Long-term results of RTOG 91-11: three non-surgical strategies to preserve the larynx](https://onco.cc/key-papers/paper-rtog-91-11-long-term-forastiere-jco-2013/), [Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)](https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/), [Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343](https://onco.cc/key-papers/paper-hughes-j-clin-oncol/), [Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group](https://onco.cc/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/), [Management of Cancer Cachexia: ASCO Guideline](https://onco.cc/key-papers/paper-roeland-j-clin-oncol/), [Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-bohlius-j-clin-oncol/), [Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline](https://onco.cc/key-papers/paper-paice-j-clin-oncol/), [Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline](https://onco.cc/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/), [Management of Male Breast Cancer: ASCO Guideline](https://onco.cc/key-papers/paper-hassett-j-clin-oncol/), [Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy](https://onco.cc/key-papers/paper-symmans-j-clin-oncol/), [Mesothelin Immunotherapy for Cancer: Ready for Prime Time?](https://onco.cc/key-papers/paper-mesothelin-mesothelioma-j-clin-oncol-2016/), [MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression](https://onco.cc/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/), [Metastatic Pancreatic Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/), [Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial](https://onco.cc/key-papers/paper-bielack-j-clin-oncol/), [Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO](https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/), [Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group](https://onco.cc/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/), [Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing](https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/), [Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)](https://onco.cc/key-papers/paper-flaherty-j-clin-oncol/), [MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy](https://onco.cc/key-papers/paper-nct02107703-j-clin-oncol-2017/), [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/), [MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia](https://onco.cc/key-papers/paper-morpho-gilteritinib-levis-jco-2024/), [Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia](https://onco.cc/key-papers/paper-amer-zeidan-j-clin-oncol-2021/), [Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib](https://onco.cc/key-papers/paper-kras-nsclc-j-clin-oncol-2005/), [National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer](https://onco.cc/key-papers/paper-childers-j-clin-oncol/), [NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer](https://onco.cc/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/), [Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline](https://onco.cc/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/), [Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial](https://onco.cc/key-papers/paper-nct02938299-j-clin-oncol-2026-update/), [Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases](https://onco.cc/key-papers/paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010/), [Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial](https://onco.cc/key-papers/paper-nala-j-clin-oncol-2020/), [Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer](https://onco.cc/key-papers/paper-qin-j-clin-oncol/), [Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/key-papers/paper-magnitude-j-clin-oncol-2023/), [Nivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis](https://onco.cc/key-papers/paper-dangelo-mucosal-melanoma-pooled-jco-2017/), [Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study](https://onco.cc/key-papers/paper-azad-j-clin-oncol/), [Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer](https://onco.cc/key-papers/paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011/), [Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer](https://onco.cc/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/), [NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases](https://onco.cc/key-papers/paper-nrg-cc001-brown-jco-2020/), [O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation](https://onco.cc/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/), [Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/), [ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma](https://onco.cc/key-papers/paper-arrillaga-romany-j-clin-oncol/), [Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial](https://onco.cc/key-papers/paper-nct06106308-j-clin-oncol-2025/), [OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus](https://onco.cc/key-papers/paper-andtbacka-optim-talimogene-jco-2015/), [Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)](https://onco.cc/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/), [Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial](https://onco.cc/key-papers/paper-penelope-b-j-clin-oncol-2021/), [Palliative Care for Patients With Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-sanders-j-clin-oncol/), [Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study](https://onco.cc/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/), [Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study](https://onco.cc/key-papers/paper-antoine-italiano-j-clin-oncol-2022/), [Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study](https://onco.cc/key-papers/paper-keynote-407-j-clin-oncol-2023-update/), [Perioperative durvalumab for resectable non-small-cell lung cancer](https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/), [PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer](https://onco.cc/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/), [Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven](https://onco.cc/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/), [Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater](https://onco.cc/key-papers/paper-overman-capox-small-bowel-adenocarcinoma-jco-2009/), [Phase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma](https://onco.cc/key-papers/paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019/), [Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma](https://onco.cc/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/), [Phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma](https://onco.cc/key-papers/paper-vogelzang-pemetrexed-mesothelioma-jco-2003/), [Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)](https://onco.cc/key-papers/paper-nct03974022-j-clin-oncol-2025/), [Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project](https://onco.cc/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/), [Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A](https://onco.cc/key-papers/paper-reckamp-j-clin-oncol/), [Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2](https://onco.cc/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/), [Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial](https://onco.cc/key-papers/paper-eckstein-j-clin-oncol/), [Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study](https://onco.cc/key-papers/paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011/), [Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression](https://onco.cc/key-papers/paper-crane-smad4-progression-pattern-locally-advanced-jco-2011/), [Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia](https://onco.cc/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/), [Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)](https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/), [Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer](https://onco.cc/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/), [Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial](https://onco.cc/key-papers/paper-ishigami-j-clin-oncol/), [Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer](https://onco.cc/key-papers/paper-chera-j-clin-oncol/), [Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma: results from the phase III, randomized POLARGO trial](https://onco.cc/key-papers/paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026/), [POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer](https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/), [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/), [Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/), [Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology](https://onco.cc/key-papers/paper-mohile-j-clin-oncol/), [PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022/), [Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial](https://onco.cc/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/), [Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)](https://onco.cc/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/), [Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control](https://onco.cc/key-papers/paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009/), [Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study](https://onco.cc/key-papers/paper-heng-j-clin-oncol/), [Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial](https://onco.cc/key-papers/paper-kras-colorectal-j-clin-oncol-2010/), [PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours](https://onco.cc/key-papers/paper-promid-rinke-jco-2009/), [PROPHECY: prospective multicentre validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer](https://onco.cc/key-papers/paper-prophecy-arv7-validation-jco-2019/), [Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer](https://onco.cc/key-papers/paper-szmulewitz-j-clin-oncol/), [Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial](https://onco.cc/key-papers/paper-murthy-j-clin-oncol/), [PTLD-1: response to rituximab induction as a predictive marker allowing stratification into rituximab or R-CHOP consolidation in B-cell post-transplant lymphoproliferative disorder](https://onco.cc/key-papers/paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017/), [RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer](https://onco.cc/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/), [Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary](https://onco.cc/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/), [Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study](https://onco.cc/key-papers/paper-grever-j-clin-oncol/), [Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer](https://onco.cc/key-papers/paper-sandhya-j-clin-oncol/), [Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)](https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/), [Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma](https://onco.cc/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/), [Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors](https://onco.cc/key-papers/paper-elkins-j-clin-oncol/), [Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer](https://onco.cc/key-papers/paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003/), [Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://onco.cc/key-papers/paper-citron-j-clin-oncol/), [Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03](https://onco.cc/key-papers/paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018/), [Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma](https://onco.cc/key-papers/paper-chesney-j-clin-oncol/), [RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults](https://onco.cc/key-papers/paper-andrew-lassman-j-clin-oncol-2023/), [Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification](https://onco.cc/key-papers/paper-cheson-j-clin-oncol/), [Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-smith-j-clin-oncol/), [Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer](https://onco.cc/key-papers/paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008/), [Revised International Staging System (R-ISS) for multiple myeloma](https://onco.cc/key-papers/paper-r-iss-palumbo-jco-2015/), [Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States](https://onco.cc/key-papers/paper-frazier-j-clin-oncol/), [Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update](https://onco.cc/key-papers/paper-van-poznak-j-clin-oncol/), [ROS1 rearrangements define a unique molecular class of lung cancers](https://onco.cc/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/), [ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma](https://onco.cc/key-papers/paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023/), [RTOG 9402: PCV chemotherapy before radiotherapy for anaplastic oligodendroglioma, long-term results](https://onco.cc/key-papers/paper-rtog-9402-cairncross-jco-2013/), [Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial](https://onco.cc/key-papers/paper-harrison-j-clin-oncol/), [Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial](https://onco.cc/key-papers/paper-checkmate-358-j-clin-oncol-2019/), [SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals](https://onco.cc/key-papers/paper-sempet-de-santis-jco-2004/), [Single-injection depot progesterone before surgery and survival in operable breast cancer](https://onco.cc/key-papers/paper-badwe-progesterone-jco-2011/), [SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/key-papers/paper-peters-j-clin-oncol/), [Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ](https://onco.cc/key-papers/paper-morrow-j-clin-oncol/), [Somatic activation of KIT in distinct subtypes of melanoma](https://onco.cc/key-papers/paper-curtin-kit-melanoma-jco-2006/), [Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial](https://onco.cc/key-papers/paper-palma-j-clin-oncol/), [Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma](https://onco.cc/key-papers/paper-zhukova-tp53-medulloblastoma-jco-2013/), [SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-sunrise-1-jco-2025/), [Supervised risk predictor of breast cancer based on intrinsic subtypes](https://onco.cc/key-papers/paper-parker-j-clin-oncol/), [Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study](https://onco.cc/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/), [SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma](https://onco.cc/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/), [Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography](https://onco.cc/key-papers/paper-mikhael-j-clin-oncol/), [Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials](https://onco.cc/key-papers/paper-di-maio-j-clin-oncol/), [Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline](https://onco.cc/key-papers/paper-gordan-j-clin-oncol/), [Systemic therapy in the palliative management of advanced salivary gland cancers (review)](https://onco.cc/key-papers/paper-laurie-licitra-salivary-systemic-jco-2006/), [Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial](https://onco.cc/key-papers/paper-irwin-j-clin-oncol/), [Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study](https://onco.cc/key-papers/paper-hainsworth-j-clin-oncol/), [Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival](https://onco.cc/key-papers/paper-blinatumomab-all-leukemia-j-clin-oncol-2011/), [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://onco.cc/key-papers/paper-luminosity-j-clin-oncol-2024/), [The International Neuroblastoma Risk Group (INRG) classification system](https://onco.cc/key-papers/paper-inrg-cohn-jco-2009/), [The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival](https://onco.cc/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/), [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://onco.cc/key-papers/paper-shen-j-clin-oncol/), [Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure](https://onco.cc/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/), [TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/), [Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial](https://onco.cc/key-papers/paper-nct06968585-j-clin-oncol-2026/), [Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial](https://onco.cc/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/), [Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study](https://onco.cc/key-papers/paper-luca-gianni-j-clin-oncol-2022/), [Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline](https://onco.cc/key-papers/paper-andrew-lassman-j-clin-oncol-2022/), [Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study](https://onco.cc/key-papers/paper-dix-j-clin-oncol-2018/), [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://onco.cc/key-papers/paper-scher-j-clin-oncol/), [TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration](https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/), [TROPHIMMUN cohort A: avelumab in gestational trophoblastic tumours resistant to single-agent chemotherapy](https://onco.cc/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020/), [TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival](https://onco.cc/key-papers/paper-tropion-breast01-jco-2024/), [TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma](https://onco.cc/key-papers/paper-hammel-j-clin-oncol/), [Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study](https://onco.cc/key-papers/paper-nct04579380-j-clin-oncol-2023/), [Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study](https://onco.cc/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/), [Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers](https://onco.cc/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/), [Underuse of trimodality treatment and survival in inflammatory breast cancer (National Cancer Data Base)](https://onco.cc/key-papers/paper-rueth-inflammatory-breast-trimodality-jco-2014/), [Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received](https://onco.cc/key-papers/paper-schnipper-j-clin-oncol/), [Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-andrea-decensi-j-clin-oncol-2019/), [Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update](https://onco.cc/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/), [VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801](https://onco.cc/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/), [Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study](https://onco.cc/key-papers/paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019/), [Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-key-j-clin-oncol/), [Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)](https://onco.cc/key-papers/paper-robinson-vismodegib-shh-medulloblastoma-jco-2015/), [Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer](https://onco.cc/key-papers/paper-kras-colorectal-j-clin-oncol-2008/), [ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer](https://onco.cc/key-papers/paper-zeta-vandetanib-mtc-wells-jco-2012/), [Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab](https://onco.cc/key-papers/paper-nct04036682-j-clin-oncol-2025/)
- people: [Ate van der Zee](https://onco.cc/people/ate-van-der-zee/), [Marc Ychou](https://onco.cc/people/marc-ychou/), [Nadine Karema](https://onco.cc/people/nadine-karema/), [Robert G. Uzzo](https://onco.cc/people/robert-uzzo/), [Vasanta Nanduri](https://onco.cc/people/vasanta-nanduri/)

---
JSON: https://onco.cc/api/v1/entities/jco.json